Cargando…

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins

BACKGROUND: Recent studies have demonstrated a causal role for elevated triglycerides (TG) in incident cardiovascular (CV) events in patients with established coronary heart disease (CHD) and those with CV risk factors alone, particularly diabetes. OBJECTIVE: Using a large cohort of U.S. veterans wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leatherman, Sarah, Ferguson, Ryan, Hau, Cynthia, Harrington, Kelly, Granowitz, Craig, Philip, Sephy, Toth, Peter Paul, Bhatt, Deepak, Boden, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673755/ https://www.ncbi.nlm.nih.gov/pubmed/36407462 http://dx.doi.org/10.3389/fcvm.2022.982815

Ejemplares similares

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
por: Nichols, Gregory A., et al.
Publicado: (2018)

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
por: Toth, Peter P, et al.
Publicado: (2019)

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
por: Toth, Peter P., et al.
Publicado: (2018)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2019)

Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high‐risk statin‐treated patients: A large administrative retrospective analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Beyond LDL: Understanding Triglyceride-Rich Lipoproteins to Tackle Residual Risk
por: Gugliucci, Alejandro
Publicado: (2023)

Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
por: Clem, James R, et al.
Publicado: (2009)

Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?
por: Habon, Tamas, et al.
Publicado: (2016)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study
por: Wagner, Jeffrey R., et al.
Publicado: (2022)

Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages
por: Puig, Núria, et al.
Publicado: (2020)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Baseline hemoglobin A1c and risk of statin-induced diabetes: results of Veterans Affairs Database analysis
por: Ziganshina, Anna P, et al.
Publicado: (2022)

Posttraumatic stress disorder, depression, and non-fatal intentional self-harm in Massachusetts Veterans
por: Gradus, Jaimie L, et al.
Publicado: (2014)

Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome
por: Hori, Masakazu, et al.
Publicado: (2021)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

Triglycerides and Residual Atherosclerotic Risk
por: Raposeiras-Roubin, Sergio, et al.
Publicado: (2021)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol
por: Hirano, Tsutomu, et al.
Publicado: (2022)

Targets of statins intervention in LDL-C metabolism: Gut microbiota
por: Sun, ChangXin, et al.
Publicado: (2022)

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
por: Budoff, Matthew J, et al.
Publicado: (2020)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Effect of sesamin on serum cholesterol and triglycerides levels in LDL receptor-deficient mice
por: Peñalvo, José L., et al.
Publicado: (2006)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta‐Analysis
por: Zhang, Xin‐Lin, et al.
Publicado: (2019)

Epidemiology and burden of influenza in the U.S. Department of Veterans Affairs
por: Lucero‐Obusan, Cynthia, et al.
Publicado: (2017)

Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
por: Kim, Kyungpil, et al.
Publicado: (2014)

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
por: Krähenbühl, Stephan, et al.
Publicado: (2016)

Evaluation of LDL goal achievement in statin consumption, south east of Iran
por: Aghasizadeh, Malihe, et al.
Publicado: (2021)

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs
por: Aggarwal, Dimple, et al.
Publicado: (2005)

Racial and Ethnic Disparities in U.S. Veteran Health Characteristics
por: Ward, Rachel E., et al.
Publicado: (2021)

Detection of quantitative trait loci affecting serum cholesterol, LDL, HDL, and triglyceride in pigs
por: Uddin, Muhammad Jasim, et al.
Publicado: (2011)

Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_86qbt25u74sd0k24rtl8rhmu89